Company Overview and News

 
Jane's April Dividend Income Tracker - Retirement Accounts

2018-05-15 seekingalpha
This is the second month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her combined dividend income totaled $1,300.03.

 
John And Jane - April Dividend Income Tracker - Taxable Account

2018-05-08 seekingalpha
This is the 6th month I have officially tracked dividend income, and it was slightly below expectations with a total of $619.98 of dividends received.

 
MSB / Mesabi Trust 8-K (Current Report)

2018-04-27 sec.gov
msb_8-K_20180426 UNITED STATES

1
MSB / Mesabi Trust 8-K (Current Report)

2018-04-13 sec.gov
msb_Current_Folio_8K

1
MSB / Mesabi Trust 10-K (Annual Report)

2018-04-13 sec.gov
msb_CurrentFolio_10K Table of Contents

 
Jane's March Dividend Income Tracker - Retirement Accounts

2018-04-09 seekingalpha
This is the first month I have officially tracked dividend income (in an article) in Jane's Traditional and Roth IRA Accounts. Her combined dividend income totaled $883.70.

 
John And Jane - March Dividend Income Tracker - Taxable Account

2018-04-03 seekingalpha
This is the 5th month I have officially tracked dividend income and it was slightly above expectations with a total of $929.59 of dividends received.

1
Lithium Junior Miner News For The Month Of March 2018

2018-03-28 seekingalpha
Lithium spot and contract price news - Lithium spot prices moved sideways, whilst 2018 global LCE contract prices are up about 20%.

 
7 A-Rated Small-Cap Stocks to Buy | InvestorPlace

2018-03-16 investorplace
By all evidence, it looks like the U.S. economy and the global economy are finally recovering — without the aid of central banks at this point.

1
John And Jane - February Dividend Income Tracker - Taxable Account

2018-03-05 seekingalpha
This is the 4th month I have officially tracked dividend income and it was the strongest month yet with a total of $1271.50 of dividends received.

 
A Look At Mesabi Trust

2018-02-26 seekingalpha
Mesabi Trust has recently bounced back, with current fiscal year revenue roughly triple that of last years.

 
Mesabi Trust: 18% Dividend Yield With Price Appreciation Potential

2018-02-20 seekingalpha
With a low valuation and steady growth for iron ore, the Mesabi Trust should thrive over many years.

 
What Retirees Need To Consider Now That Market Volatility Is Back

2018-02-13 seekingalpha
I think we can all agree that we've forgotten what volatility looks like because of the ever-increasing valuations associated with equities.

1
John And Jane - January Dividend Income Tracker

2018-02-05 seekingalpha
This is the third month I have officially tracked dividend income and it was another strong month with a total of $1020.98 of dividends received.

 
MSB / Mesabi Trust ER

2018-02-02 sec.gov
Mail Stop 3561 December 20, 2017 Via E-mail Jeffrey Schoenfeld Mesabi Trust c/o Deutsche Bank Trust Company Americas Trust & Agency Services 60 Wall Street, 16 th Floor New York, New York 10005 Re: Mesabi Trust Form 10-K for Fiscal Year Ended January 31, 2017 Filed April 14, 2017 File No. 001-04488 Dear Mr. Schoenfeld: We have reviewed your filing and have the following comment.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 590672101